UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Author's Avatar
Apr 19, 2023

Data presented were crucial to initiating its ongoing Phase 1 clinical trial with Decoy 20 in solid tumors